Avalon globocare extends exclusivity agreement to distribute ketoair breathalyzer device and ai-enabled software in north america, south america, united kingdom and european union

Freehold, n.j., march 28, 2024 (globe newswire) -- avalon globocare corp. (“avalon” or the “company”) (nasdaq: albt), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with qi diagnostics limited (“qi diagnostics”) to distribute the ketoair™, a breathalyzer device and related accessories, including current and future models, in key regions including north america, south america, the united kingdom, and the european union.
ALBT Ratings Summary
ALBT Quant Ranking